Ascentage Pharma Group International (HKG:6855)
Hong Kong · Delayed Price · Currency is HKD 39.46
-0.62 (-1.55%)
May 28, 2026, 10:10 AM HKT
HKG:6855 Revenue
In the year 2025, Ascentage Pharma Group International had annual revenue of 574.12M CNY, down -41.46%. Ascentage Pharma Group International had revenue of 340.42M in the half year ending December 31, 2025, with 329.37% growth.
Revenue
574.12M CNY
Revenue Growth
-41.46%
P/S Ratio
23.09
Revenue / Employee
948.96K CNY
Employees
605
Market Cap
14.75B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 574.12M | -406.53M | -41.46% |
| Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
| Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
| Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
| Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
| Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
| Dec 31, 2019 | 14.51M | 7.71M | 113.21% |
| Dec 31, 2018 | 6.81M | 479.00K | 7.57% |
| Dec 31, 2017 | 6.33M | -1.34M | -17.46% |
| Dec 31, 2016 | 7.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zai Lab | 3.55B |
| Duality Biotherapeutics | 2.06B |
| Everest Medicines | 1.90B |
| HBM Holdings | 1.23B |
| Keymed Biosciences | 797.12M |
| CStone Pharmaceuticals | 299.99M |
| Nanjing Leads Biolabs | 197.25M |
| CARsgen Therapeutics Holdings | 139.84M |
Ascentage Pharma Group International News
- 6 days ago - Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 - GlobeNewsWire
- 15 days ago - Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress - GlobeNewsWire
- 15 days ago - Ascentage Pharma to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Ascentage Pharma initiated with a Buy at Deutsche Bank - TheFly
- 5 weeks ago - Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026 - GlobeNewsWire
- 5 weeks ago - Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting - GlobeNewsWire
- 2 months ago - Full Year 2025 Ascentage Pharma Group International Earnings Presentation Transcript - GuruFocus
- 2 months ago - Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates - GlobeNewsWire